44 results on '"Schmidt, Albrecht G"'
Search Results
2. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19
3. Correction to: Informed consent and informed intervention: SARS‑CoV‑2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing
4. Informed consent and informed intervention: SARS-CoV-2 vaccinations not just call for disclosure of newly emerging safety data but also for hypothesis generation and testing
5. Allosteric targeting resolves limitations of earlier LFA-1 directed modalities
6. Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction — Results of the Aldo-DHF trial
7. Compensated hypertrophy of cardiac ventricles in aged transgenic FVB/N mice overexpressing calsequestrin
8. Genetic Alterations and Modeling of Cardiovascular Physiology
9. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial
10. Association of HLA and Mutated CCR5 With the Clinical Course of the Disease in Subjects With mild / moderate disease following COVID-19 infection
11. Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality
12. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction: The Aldo-DHF Randomized Controlled Trial
13. Phospholamban: A Promising Therapeutic Target in Heart Failure?
14. Anti‐αLβ2 antibodies reveal novel endocytotic cross‐modulatory functionality
15. Rationale and design of the ‘aldosterone receptor blockade in diastolic heart failure’ trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldo-DHF)
16. Genetic Alterations and Modeling of Cardiovascular Physiology
17. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy
18. Evaluation of Left Ventricular Diastolic Function from Spectral and Color M-mode Doppler in Genetically Altered Mice
19. Galectin‐3 in patients with heart failure with preserved ejection fraction: results from the Aldo‐ DHF trial
20. Celecoxib modulates hypertrophic signalling and prevents load‐induced cardiac dysfunction
21. High intracellular Na+preserves myocardial function at low heart rates in isolated myocardium from failing hearts
22. Chronic SR Ca 2+ -ATPase Inhibition Causes Adaptive Changes in Cellular Ca 2+ Transport
23. Type 1 Phosphatase, a Negative Regulator of Cardiac Function
24. Letter to the Editor: Re-evaluation of Heart Failure in Transgenic Mice with Impaired SR Ca2+Release
25. Superinhibition of Sarcoplasmic Reticulum Function by Phospholamban Induces Cardiac Contractile Failure
26. Rescue of Contractile Parameters and Myocyte Hypertrophy in Calsequestrin Overexpressing Myocardium by Phospholamban Ablation
27. Interactions Between Phospholamban and β-Adrenergic Drive May Lead to Cardiomyopathy and Early Mortality
28. Cardiac-specific Overexpression of Calsequestrin Results in Left Ventricular Hypertrophy, Depressed Force–frequency Relation and Pulsus Alternans In Vivo
29. The Transgenic Expression of Highly Inhibitory Monomeric Forms of Phospholamban in Mouse Heart Impairs Cardiac Contractility
30. Maximal Inhibition of SERCA2 Ca2+ Affinity by Phospholamban in Transgenic Hearts Overexpressing a Non-phosphorylatable Form of Phospholamban
31. Cardiac-specific Overexpression of a Superinhibitory Pentameric Phospholamban Mutant Enhances Inhibition of Cardiac Functionin Vivo
32. Polymorphic SERCA2a variants do not account for inter-individual differences in phospholamban-SERCA2a interactions in human heart failure
33. High intracellular Na+ preserves myocardial function at low heart rates in isolated myocardium from failing hearts
34. Chronic SR Ca2+-ATPase Inhibition Causes Adaptive Changes in Cellular Ca2+ Transport.
35. Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy
36. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state
37. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure
38. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis
39. Maximal Inhibition of SERCA2 Ca2+Affinity by Phospholamban in Transgenic Hearts Overexpressing a Non-phosphorylatable Form of Phospholamban*
40. Relevance of stretch-induced phosphorylation of MAPK and p90rsk in human myocardium.
41. High intracellular Na+ preserves myocardial function at low heart rates in isolated myocardium from failing hearts.
42. Chronic SR Ca2+-ATPase inhibition causes adaptive changes in cellular Ca2+ transport.
43. Compensated hypertrophy of cardiac ventricles in aged transgenic FVB/N mice overexpressing calsequestrin.
44. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.